PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Parexel Announces Innovative Patient Centric Partnership with Cancer Hospital Chinese Academy of Medical Sciences

Collaboration seeks to obtain direct insights from patients to improve clinical trial accessibility, drive efficiency 

Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced an innovative partnership with Cancer Hospital Chinese Academy of Medical Sciences (CHCAMS) to develop patient-centric protocol designs and methodologies for decentralized clinical trials in China. The collaboration will also include quantitative research to improve the clinical trial experience of oncology patients.

“We are honored to be partnering with CHCAMS,” said Vicky Hsu, Corporate Vice President, Greater China Region Head and Head of Asia/Pacific Biotech Operations for Parexel. “The Cancer Hospital Chinese Academy of Medical Sciences is a highly-regarded, nationwide cancer hospital that shares Parexel’s Patients-First focus and our collaboration further illustrates our commitment to elevate the patient perspective and ensure their unique needs and challenges help shape future clinical studies.”

Established in 1958, CHCAMS is linked to other institutions including the China National Cancer Center (NCC) and has been conducting clinical trials for 60 years. It is the first cancer hospital in China and to date, has conducted more than 3,000 clinical studies.

“Our partnership with Parexel will allow us to obtain direct insights from patients to help improve their clinical trial experience and improve overall clinical trial accessibility,” said Ning Li, Assistant Dean, Cancer Ho…

Read More...
Parexel Announces Innovative Patient Centric Partnership with Cancer Hospital Chinese Academy of Medical Sciences

Articles